Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Two sides of the same coin: protective versus pathogenic mesentery in inflammatory bowel diseases - a comprehensive review

Lu H., Feng Z., Aden K., Cong Y., Liu Z., Liu Z.

Narrative Review on Chronic Inflammation, Autoimmune Research, published in Int J Surg (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Int J Surg (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40717577
PMCID
PMC12626502
DOI
10.1097/js9.0000000000003075
Citations
3

Abstract (original English)

The mesentery, a membranous structure containing blood vessels, nerves, and lymphatics and attaching the intestines to the posterior abdominal wall, plays a crucial role in the pathogenesis of inflammatory bowel disease (IBD). In this review, we describe the signature features of the mesentery in IBD, including mesenteric hypervascularity (the comb sign) and edema, creeping fat generation, mesenteric fibrofatty proliferation, mesenteric lymphadenopathy, stenosis/sacculation, and hyperplasia of neurological components. These traits trigger a surge in the production of chemokines and proinflammatory cytokines within the mesentery and cause a significant buildup of inflammatory immune cells, exacerbating intestinal inflammation. Contradictorily, the intact lymphatic mesentery, in conjunction with the intestinal mucosa, immune cells, and commensal bacteria, constitutes a mechanical barrier that restricts bacterial penetration, thus preventing the initiation of abnormal immune responses. The mesentery also contributes to the processes of fibrosis and stenosis by secreting adiponectin and anti-inflammatory cytokines and suppresses intestinal perforation and the translocation of bacteria to the peritoneum, leading to the containment and remission of intestinal inflammation. Moreover, we also propose novel diagnostic strategies and therapeutic interventions that target the mesentery in

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
MesenteryHumansInflammatory Bowel Diseases

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research